letrozole
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Locally Advanced Breast Cancer
Conditions
Locally Advanced Breast Cancer, Hormone Receptor Positive，HER2-negative Breast Cancer
Trial Timeline
Mar 1, 2023 → Mar 25, 2026
NCT ID
NCT05809024About letrozole
letrozole is a approved stage product being developed by Jiangsu Hengrui Medicine for Locally Advanced Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05809024. Target conditions include Locally Advanced Breast Cancer, Hormone Receptor Positive，HER2-negative Breast Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Locally Advanced Breast Cancer were approved
Approved (4) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05809024 | Approved | Recruiting |
Competing Products
20 competing products in Locally Advanced Breast Cancer